PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33704530-7 2021 A slight increase of T-bet-positive TH1-equivalents was identifiable under lenalidomide. Lenalidomide 75-87 negative elongation factor complex member C/D Homo sapiens 36-39 29951065-12 2018 In summary, DCs derived from monocytes in the presence of lenalidomide present a semi-mature phenotype, increased phagocytic capacity, reduced production of proinflammatory cytokines, and the ability to polarize T-cells toward predominant Th1-type responses; these are qualities that might be useful in the development of new immunotherapeutic treatments. Lenalidomide 58-70 negative elongation factor complex member C/D Homo sapiens 239-242 30104242-0 2018 Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia. Lenalidomide 101-113 negative elongation factor complex member C/D Homo sapiens 14-17 30104242-6 2018 Within days of starting lenalidomide, T cells increased in the tumor microenvironment and showed Th1-type polarization. Lenalidomide 24-36 negative elongation factor complex member C/D Homo sapiens 97-100 30104242-11 2018 Taken together, our data demonstrate that lenalidomide induced Th1 immunity in the lymph node that is associated with clinical response. Lenalidomide 42-54 negative elongation factor complex member C/D Homo sapiens 63-66 27889516-7 2017 These results suggest that LEN enhanced the function of DCs generated from patients with multiple myeloma by stimulating the capacity of allogeneic T cells, inhibiting the generation of immunosuppressive cells, inducing naive T cells toward Th1 polarization, and generating potent myeloma-specific cytotoxic T lymphocytes. Lenalidomide 27-30 negative elongation factor complex member C/D Homo sapiens 241-244 27698446-0 2017 Expansion of Th1-like Vgamma9Vdelta2T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid. Lenalidomide 69-81 negative elongation factor complex member C/D Homo sapiens 13-16 27668268-0 2015 Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors. Lenalidomide 0-12 negative elongation factor complex member C/D Homo sapiens 23-26 27668268-5 2015 Lenalidomide increased the anti-tumor activities of XBP1-CTL memory subsets, which were associated with expression of Th1 transcriptional regulators (T-bet, Eomes) and Akt activation, thereby resulting in enhanced IFN-gamma production, granzyme B upregulation and specific CD28/CD38-positive and CTLA-4/PD-1-negative cell proliferation. Lenalidomide 0-12 negative elongation factor complex member C/D Homo sapiens 118-121 18980990-9 2008 Importantly, lenalidomide further augmented the Th1 polarization by iNKT cell lines via increased Th1 cytokine production and reduced Th2 cytokine production. Lenalidomide 13-25 negative elongation factor complex member C/D Homo sapiens 48-51 23609417-0 2013 Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma. Lenalidomide 81-93 negative elongation factor complex member C/D Homo sapiens 15-18 23609417-6 2013 Furthermore, Len enhanced the production of both Th1 and Th2 cytokines in normal peripheral blood mononuclear cells and in patient bone marrow mononuclear cells containing primary myeloma cells and lymphocytes. Lenalidomide 13-16 negative elongation factor complex member C/D Homo sapiens 49-52 18980990-9 2008 Importantly, lenalidomide further augmented the Th1 polarization by iNKT cell lines via increased Th1 cytokine production and reduced Th2 cytokine production. Lenalidomide 13-25 negative elongation factor complex member C/D Homo sapiens 98-101